Skip to main content
Premium Trial:

Request an Annual Quote

Crossing Their Fingers

Human Genome Sciences plans to release late-stage clinical data on Benlysta, its experimental drug for lupus, on Monday, reports Dow Jones Newswires. The story adds that lupus is "a notoriously hard-to-treat autoimmune disease that hasn't seen a new therapy in decades." Human Genome Sciences partnered with GlaxoSmithKline and worked closely with FDA to design its phase III trial after the phase II trial failed. The article says that if this first trial fails — Barclays analyst Jim Birchenough estimates an 85 percent chance of failure — the company's stock will likely drop to about $1; but if it meets its endpoints, the stock could reach higher than $10.

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.